Compound ID | 1234

Update compound information

Debio1453

Spectrum of activity: Gram-negative
Details of activity: Inhibits FabI, which determins the completing of each cycle of elongation in the fatty acid synthesis. Neisseria gonorrhoeae
Institute where first reported: Debiopharm International SA
Highest development stage: Preclinical
Development status: Active
Chemical structure(s):
Click here for structure editor
Molecular weight: 404.46
Iso. SMILES: C[C@H]1C(=O)NCC2=C(N1)N=CC(=C2)/C=C/C(=O)N(C)CC3=C(C4=CC=CC=C4O3)C
InChI Key: DWTASDVFEKBNET-HVHJFMEUSA-N
Can. SMILES: CC1=C(CN(C)C(=O)/C=C/C2=CN=C3C(=C2)CNC(=O)[C@H](C)N3)OC4=C1C=CC=C4
InChI: InChI=1S/C23H24N4O3/c1-14-18-6-4-5-7-19(18)30-20(14)13-27(3)21(28)9-8-16-10-17-12-25-23(29)15(2)26-22(17)24-11-16/h4-11,15H,12-13H2,1-3H3,(H,24,26)(H,25,29)/b9-8+/t15-/m0/s1
External links:
Structure link: https://pubchem.ncbi.nlm.nih.gov/compound/59277625
Guide to Pharmacology: Debio 1453
Citation: https://www.debiopharm.com/debiopharm-international/press-releases/debiopharm-international-sa-awarded-2-6-million-grant-from-carb-x-to-support-development-of-debio-1453-to-fight-drug-resistant-gonorrhea/

AntibioticDB is supported by GARDP.

If you have feedback, experience problems, or are interested in a collaboration, please contact us. | Terms and conditions

The content of this site is intended for educational and scientific research purposes only and not as a source of medical advice or consultation.